ReviewOncotarget2014
HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.
Review in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 65 citations in OpenAlex.
- Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients withTranslational lung cancer research · 2025Article
- Kidney Injury in Patient with Non-small-cell Lung Cancer Receiving Tepotinib.Internal medicine (Tokyo, Japan) · 2025Article
- Exploring Ototoxicity Associated with Capmatinib: Insights from a Real-World Data Analysis of the FDA Adverse Event Reporting System (FAERS) Database.Clinical epidemiology · 2025Article
- Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System.PloS one · 2025Article
- Targeting RTKs/nRTKs as promising therapeutic strategies for the treatment of triple-negative breast cancer: evidence from clinical trials.Military Medical Research · 2024Review
- Stroma AReactive Invasion Front Areas (SARIFA) predict poor survival in adenocarcinomas of the stomach and gastrooesophageal junction: a validation study.Virchows Archiv : an international journal of pathology · 2024Article
- E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network.Cancer research communications · 2024Article
- Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges.Frontiers in molecular biosciences · 2024Review
- c-MetBiomedicines · 2023Article
- HGF/c-Met signaling promotes the migration and proliferation of deer antler MSCs.Scientific reports · 2023Article
- Gumarontinib in patients with non-small-cell lung cancer harbouringEClinicalMedicine · 2023Article
- Review
- Predictive biomarkers in gastric cancer.Journal of cancer research and clinical oncology · 2023Review
- Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors.Targeted oncology · 2022Article
- Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.Clinical lung cancer · 2022Article
- Capmatinib successfully overcomes tepotinib-induced intolerable peripheral edema.Thoracic cancer · 2021Article
- The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer.Frontiers in oncology · 2021Article
- Tepotinib Inhibits the Epithelial-Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3β, E-Cadherin, and Mucin 5AC and 6 Levels.International journal of molecular sciences · 2020Article
- Article
- Identification of key genes and associated pathways in KIT/PDGFRA wild‑type gastrointestinal stromal tumors through bioinformatics analysis.Molecular medicine reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant activation of the HGF/MET signaling axis has been strongly implicated in the malignant transformation and progression of gastroesophageal cancer (GEC). MET receptor overexpression in tumor samples from GEC patients has been consistently correlated with an aggressive metastatic phenotype and poor prognosis. In preclinical GEC models, abrogation of HGF/MET signaling has been shown to induce tumor regression as well as inhibition of metastatic dissemination. Promising clinical results in patient subsets in which MET is overexpressed have spurned several randomized studies of HGF/MET-directed agents, including two pivotal global Phase III trials. Available data highlight the need for predictive biomarkers in order to select patients most likely to benefit from HGF/MET inhibition. In this review, we discuss the current knowledge of mechanisms of MET activation in GEC, the current status of the clinical evaluation of MET-targeted therapies in GEC, characteristics of ongoing randomized GEC trials and the associated efforts to identify and validate biomarkers. We also discuss the considerations and challenges for HGF/MET inhibitor drug development in the GEC setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.